Published online before print August 21, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
* Institute of Biochemistry G. Fornaini, University of Urbino, Via Saffi 2, 61029, Urbino, Italy;
Dept. Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy and
INMI L. Spallanzani, Via Portuense 292, 00149 Rome, Italy
1 Correspondence: Institute of Biological Chemistry "G. Fornaini", University of Urbino, Via Saffi 2, 61029, Urbino (PU) ITALY Email: magnani{at}uniurb.it
Current highly active antiretroviral therapy (HAART) cannot eliminate HIV-1 from infected persons, mainly because of the existence of refractory viral reservoir(s). Beyond latently-infected CD4+-T lymphocytes, macrophages (M/M) are important persistent reservoirs for HIV in vivo, that represent a major obstacle to HIV-1 eradication. Therefore, a rational therapeutic approach directed to the selective elimination of long-living HIV-infected M/M may be relevant in the therapy of HIV infection. Here we report that HIV-1 chronic infection of human macrophages results in the marked increase of expression and phosphorylation of STAT1, a protein involved in the regulation of many functions such as cell growth, differentiation, and maintenance of cellular homeostasis, thereby providing a new molecular target for drug development. A single and brief exposure to 9-(ß-D-arabinofuranosyl)-2-fluoroadenine 5'-monophosphate (FaraAMP, Fludarabine), a potent antileukemic nucleoside analog active against STAT1 expressing cells, selectively kills macrophage cultures infected by HIV-1 without affecting uninfected macrophages. Furthermore, encapsulation of Fludarabine into autologous erythrocytes (RBC) and targeting to macrophages through a single-18 h treatment with drug-loaded RBC, not only abolishes the Fludarabine-mediated toxic effect on non-phagocytic cells, but also enhances the selective killing of HIV-infected macrophages. As a final result, a potent (>98%) and long-lasting (at least 4 weeks without rebound) inhibition of virus release from drug-loaded RBC-treated chronically-infected macrophages was achieved. Taken together, the evidence of HIV-1-induced increase of STAT1, and the availability of a selective drug targeting system, may prove useful in the design of new pharmacological treatments to clear the HIV-1 macrophage reservoir.
Key Words: macrophages (M/M) • Fludarabine • erythrocytes (RBC)
This article has been cited by other articles:
 |
|
 |
|
  A. Chaudhuri, B. Yang, H. E. Gendelman, Y. Persidsky, and G. D. Kanmogne STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier Blood, February 15, 2008; 111(4): 2062 - 2072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Qian, H. An, Y. Yu, S. Liu, and X. Cao TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation Blood, April 15, 2007; 109(8): 3308 - 3315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Cervasi, M. Paiardini, S. Serafini, A. Fraternale, M. Menotta, J. Engram, B. Lawson, S. I. Staprans, G. Piedimonte, C. F. Perno, et al. Administration of Fludarabine-Loaded Autologous Red Blood Cells in Simian Immunodeficiency Virus-Infected Sooty Mangabeys Depletes pSTAT-1-Expressing Macrophages and Delays the Rebound of Viremia after Suspension of Antiretroviral Therapy. J. Virol., November 1, 2006; 80(21): 10335 - 10345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pugliese, V. Vidotto, T. Beltramo, and D. Torre Phagocytic Activity in Human Immunodeficiency Virus Type 1 Infection Clin. Vaccine Immunol., August 1, 2005; 12(8): 889 - 895. [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Collman, C.-F. Perno, S. M. Crowe, M. Stevenson, and L. J. Montaner HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions J. Leukoc. Biol., November 1, 2003; 74(5): 631 - 634. [Abstract] [Full Text] [PDF]
|
|
